<!DOCTYPE html>
<html lang="de">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Vitamin-/Cofaktor-Defekte - Vollst√§ndige Lerneinheit</title>
<style>
@import url('https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap');

* {
margin: 0;
padding: 0;
box-sizing: border-box;
}

:root {
--primary-color: #667eea;
--secondary-color: #764ba2;
--accent-color: #f093fb;
--success-color: #4facfe;
--warning-color: #fa709a;
--danger-color: #ff6b6b;
--info-color: #74b9ff;
--text-primary: #2d3748;
--text-secondary: #4a5568;
--text-muted: #718096;
--bg-white: #ffffff;
--bg-light: #f8fafc;
--bg-lighter: #f1f5f9;
--border-radius: 16px;
--border-radius-lg: 24px;
--spacing-xs: 8px;
--spacing-sm: 16px;
--spacing-md: 24px;
--spacing-lg: 32px;
--spacing-xl: 48px;
--shadow-sm: 0 4px 6px -1px rgba(0, 0, 0, 0.1);
--shadow-md: 0 10px 15px -3px rgba(0, 0, 0, 0.1);
--shadow-lg: 0 20px 25px -5px rgba(0, 0, 0, 0.1);
}

body {
font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
line-height: 1.6;
color: var(--text-primary);
background: linear-gradient(135deg, #f8fafc 0%, #e2e8f0 100%);
min-height: 100vh;
}

.container {
max-width: 1400px;
margin: 0 auto;
padding: var(--spacing-md);
}

/* Header */
.header {
background: var(--bg-white);
border-radius: var(--border-radius-lg);
padding: var(--spacing-xl);
margin-bottom: var(--spacing-lg);
text-align: center;
box-shadow: var(--shadow-md);
border: 1px solid #e2e8f0;
}

.header h1 {
background: linear-gradient(135deg, var(--primary-color), var(--secondary-color), var(--accent-color));
background-size: 200% 200%;
-webkit-background-clip: text;
-webkit-text-fill-color: transparent;
background-clip: text;
font-size: clamp(2rem, 5vw, 3.5rem);
font-weight: 700;
margin-bottom: var(--spacing-sm);
animation: gradientShift 4s ease-in-out infinite;
}

@keyframes gradientShift {
0%, 100% { background-position: 0% 50%; }
50% { background-position: 100% 50%; }
}

.header p {
color: var(--text-secondary);
font-size: 1.3rem;
font-weight: 400;
}

/* Progress bar */
.progress-container {
background: var(--bg-lighter);
border-radius: 50px;
height: 10px;
margin-top: var(--spacing-md);
overflow: hidden;
}

.progress-fill {
background: linear-gradient(90deg, var(--success-color), #00f2fe);
height: 100%;
border-radius: 50px;
transition: width 0.8s cubic-bezier(0.4, 0, 0.2, 1);
position: relative;
overflow: hidden;
}

.progress-fill::after {
content: '';
position: absolute;
top: 0;
left: 0;
width: 100%;
height: 100%;
background: linear-gradient(90deg, transparent, rgba(255, 255, 255, 0.3), transparent);
animation: progressShimmer 2s infinite;
}

@keyframes progressShimmer {
0% { transform: translateX(-100%); }
100% { transform: translateX(100%); }
}

/* Navigation */
.navigation {
background: var(--bg-white);
border-radius: var(--border-radius);
padding: var(--spacing-md);
margin-bottom: var(--spacing-lg);
display: flex;
flex-wrap: wrap;
gap: var(--spacing-sm);
justify-content: center;
box-shadow: var(--shadow-sm);
border: 1px solid #e2e8f0;
}

.nav-btn {
background: var(--bg-light);
border: 2px solid #e2e8f0;
color: var(--text-primary);
padding: 16px 24px;
border-radius: 50px;
cursor: pointer;
font-size: 14px;
font-weight: 600;
transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
text-transform: uppercase;
letter-spacing: 0.5px;
}

.nav-btn:hover {
transform: translateY(-2px);
box-shadow: var(--shadow-md);
background: var(--bg-white);
border-color: var(--primary-color);
}

.nav-btn.active {
background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
color: white;
border-color: var(--primary-color);
box-shadow: var(--shadow-md);
}

/* Content sections */
.content-section {
background: var(--bg-white);
border-radius: var(--border-radius-lg);
padding: var(--spacing-xl);
margin-bottom: var(--spacing-lg);
box-shadow: var(--shadow-md);
border: 1px solid #e2e8f0;
display: none;
}

.content-section.active {
display: block;
animation: slideInUp 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

@keyframes slideInUp {
from {
opacity: 0;
transform: translateY(20px);
}
to {
opacity: 1;
transform: translateY(0);
}
}

.section-title {
background: linear-gradient(135deg, var(--info-color), var(--primary-color));
-webkit-background-clip: text;
-webkit-text-fill-color: transparent;
background-clip: text;
font-size: 2.5rem;
font-weight: 700;
margin-bottom: var(--spacing-lg);
position: relative;
padding-bottom: var(--spacing-sm);
}

.section-title::after {
content: '';
position: absolute;
bottom: 0;
left: 0;
width: 60px;
height: 4px;
background: linear-gradient(135deg, var(--info-color), var(--primary-color));
border-radius: 2px;
animation: expandWidth 0.8s ease-out 0.3s both;
}

@keyframes expandWidth {
from { width: 0; }
to { width: 60px; }
}

/* Subsections */
.subsection {
margin-bottom: var(--spacing-lg);
padding: var(--spacing-lg);
background: var(--bg-light);
border-radius: var(--border-radius);
border: 1px solid #e2e8f0;
transition: all 0.3s ease;
}

.subsection:hover {
transform: translateY(-2px);
box-shadow: var(--shadow-md);
background: var(--bg-white);
}

.subsection h3 {
color: var(--text-primary);
margin-bottom: var(--spacing-md);
font-size: 1.5rem;
font-weight: 600;
display: flex;
align-items: center;
gap: var(--spacing-xs);
}

.subsection h3::before {
content: '';
width: 4px;
height: 24px;
background: linear-gradient(135deg, var(--success-color), #00f2fe);
border-radius: 2px;
}

.subsection h4 {
color: var(--text-primary);
margin-bottom: var(--spacing-sm);
font-size: 1.2rem;
font-weight: 600;
}

.subsection p {
color: var(--text-secondary);
margin-bottom: 1rem;
line-height: 1.7;
}

.subsection ul {
color: var(--text-secondary);
padding-left: 1.5rem;
}

.subsection li {
margin-bottom: 0.5rem;
}

/* Tables */
.clinical-table {
width: 100%;
border-collapse: separate;
border-spacing: 0;
margin: var(--spacing-md) 0;
background: var(--bg-white);
border-radius: var(--border-radius);
overflow: hidden;
box-shadow: var(--shadow-sm);
border: 1px solid #e2e8f0;
}

.clinical-table th {
background: linear-gradient(135deg, var(--info-color), var(--primary-color));
color: white;
padding: var(--spacing-md);
text-align: left;
font-weight: 600;
font-size: 0.95rem;
text-transform: uppercase;
letter-spacing: 0.5px;
}

.clinical-table td {
padding: var(--spacing-md);
border-bottom: 1px solid #f1f5f9;
transition: all 0.3s ease;
color: var(--text-primary);
}

.clinical-table tbody tr:hover {
background: #f8fafc;
}

.clinical-table tbody tr:last-child td {
border-bottom: none;
}

/* Pathway diagrams */
.pathway-diagram {
background: var(--bg-white);
border: 2px solid var(--info-color);
border-radius: var(--border-radius);
padding: var(--spacing-lg);
margin: var(--spacing-md) 0;
box-shadow: var(--shadow-sm);
}

.pathway-diagram h4 {
color: var(--text-primary);
margin-bottom: var(--spacing-md);
font-size: 1.3rem;
font-weight: 600;
text-align: center;
}

.pathway-diagram h5 {
color: var(--text-primary);
margin-bottom: var(--spacing-sm);
font-weight: 600;
}

.pathway-diagram p {
color: var(--text-secondary);
}

/* Enzyme boxes */
.enzyme-box {
display: inline-block;
background: linear-gradient(135deg, var(--info-color), var(--primary-color));
color: white;
padding: 12px 20px;
margin: 6px;
border-radius: 12px;
font-weight: 600;
transition: all 0.3s ease;
box-shadow: var(--shadow-sm);
}

.enzyme-box:hover {
transform: translateY(-2px) scale(1.05);
box-shadow: var(--shadow-md);
}

.enzyme-box.defect {
background: linear-gradient(135deg, var(--danger-color), #ee5a24);
animation: pulseGlow 2s infinite;
}

@keyframes pulseGlow {
0%, 100% {
transform: scale(1);
box-shadow: var(--shadow-sm);
}
50% {
transform: scale(1.02);
box-shadow: var(--shadow-md);
}
}

.arrow {
display: inline-block;
margin: 0 var(--spacing-sm);
font-size: 1.8rem;
color: var(--primary-color);
transition: all 0.3s ease;
}

.arrow:hover {
transform: scale(1.2);
color: var(--accent-color);
}

/* Highlight boxes */
.highlight-box {
background: linear-gradient(135deg, #fff7ed, #fed7aa);
border: 2px solid var(--warning-color);
border-radius: var(--border-radius);
padding: var(--spacing-lg);
margin: var(--spacing-md) 0;
position: relative;
box-shadow: var(--shadow-sm);
}

.highlight-box::before {
content: '‚ö†Ô∏è';
position: absolute;
top: -12px;
left: 24px;
background: linear-gradient(135deg, var(--warning-color), #fee140);
padding: 8px 12px;
border-radius: 50%;
font-size: 1.2rem;
box-shadow: var(--shadow-sm);
}

.highlight-box h4 {
color: #92400e;
margin-bottom: var(--spacing-sm);
margin-top: var(--spacing-sm);
font-weight: 600;
}

.highlight-box p, .highlight-box ul, .highlight-box li {
color: #92400e;
}

/* Case study boxes */
.case-study {
background: linear-gradient(135deg, #f0fdf4, #dcfce7);
border: 2px solid var(--success-color);
border-radius: var(--border-radius);
padding: var(--spacing-lg);
margin: var(--spacing-md) 0;
box-shadow: var(--shadow-sm);
}

.case-study h4 {
color: #166534;
margin-bottom: var(--spacing-md);
font-size: 1.3rem;
font-weight: 600;
display: flex;
align-items: center;
gap: var(--spacing-xs);
}

.case-study p, .case-study ul, .case-study li {
color: #166534;
}

/* Metabolite boxes */
.metabolite-box {
display: inline-block;
background: linear-gradient(135deg, var(--warning-color), #fee140);
color: white;
padding: 10px 16px;
margin: 4px;
border-radius: 8px;
font-size: 0.9rem;
font-weight: 500;
transition: all 0.3s ease;
box-shadow: var(--shadow-sm);
}

.metabolite-box:hover {
transform: translateY(-2px) scale(1.05);
box-shadow: var(--shadow-md);
}

/* Buttons */
.next-step {
text-align: center;
margin-top: var(--spacing-xl);
}

.next-btn {
background: linear-gradient(135deg, var(--success-color), #00f2fe);
color: white;
border: none;
padding: 18px 36px;
border-radius: 50px;
cursor: pointer;
font-size: 16px;
font-weight: 600;
transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
box-shadow: var(--shadow-md);
text-transform: uppercase;
letter-spacing: 1px;
}

.next-btn:hover {
transform: translateY(-4px) scale(1.05);
box-shadow: var(--shadow-lg);
}

/* Diagnostic flow */
.diagnostic-flow {
display: flex;
flex-direction: column;
align-items: center;
gap: var(--spacing-md);
margin: var(--spacing-md) 0;
}

.flow-step {
background: var(--bg-white);
border: 2px solid var(--info-color);
border-radius: var(--border-radius);
padding: var(--spacing-md);
max-width: 320px;
text-align: center;
transition: all 0.3s ease;
color: var(--text-primary);
box-shadow: var(--shadow-sm);
}

.flow-step:hover {
transform: translateY(-4px) scale(1.02);
box-shadow: var(--shadow-md);
}

.flow-arrow {
width: 0;
height: 0;
border-left: 12px solid transparent;
border-right: 12px solid transparent;
border-top: 20px solid var(--info-color);
animation: bounce 2s infinite;
}

@keyframes bounce {
0%, 100% { transform: translateY(0); }
50% { transform: translateY(-5px); }
}

.part-info {
background: linear-gradient(135deg, #eff6ff, #dbeafe);
border: 2px solid var(--info-color);
border-radius: var(--border-radius);
padding: var(--spacing-md);
margin-bottom: var(--spacing-lg);
text-align: center;
box-shadow: var(--shadow-sm);
}

.part-info h3 {
color: var(--info-color);
margin-bottom: var(--spacing-sm);
}

.part-info p {
color: var(--text-secondary);
}

/* Quiz containers */
.quiz-container {
background: var(--bg-light);
border-radius: var(--border-radius);
padding: var(--spacing-lg);
margin: var(--spacing-md) 0;
border: 1px solid #e2e8f0;
box-shadow: var(--shadow-sm);
}

.quiz-question {
font-weight: 600;
margin-bottom: var(--spacing-md);
color: var(--text-primary);
font-size: 1.1rem;
}

.quiz-option {
background: var(--bg-white);
border: 2px solid #e2e8f0;
border-radius: 12px;
padding: var(--spacing-md);
margin: var(--spacing-xs) 0;
cursor: pointer;
transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
font-weight: 500;
color: var(--text-primary);
}

.quiz-option:hover {
background: #eff6ff;
border-color: var(--info-color);
transform: translateX(8px) scale(1.02);
}

.quiz-option.correct {
background: linear-gradient(135deg, #f0fdf4, #dcfce7);
border-color: #22c55e;
animation: correctPulse 0.6s ease-out;
}

.quiz-option.incorrect {
background: linear-gradient(135deg, #fef2f2, #fecaca);
border-color: #ef4444;
animation: incorrectShake 0.6s ease-out;
}

@keyframes correctPulse {
0% { transform: scale(1); }
50% { transform: scale(1.05); }
100% { transform: scale(1); }
}

@keyframes incorrectShake {
0%, 100% { transform: translateX(0); }
25% { transform: translateX(-5px); }
75% { transform: translateX(5px); }
}

/* Responsive design */
@media (max-width: 768px) {
.container {
padding: var(--spacing-sm);
}

.header h1 {
font-size: 2.5rem;
}

.header p {
font-size: 1.1rem;
}

.navigation {
flex-direction: column;
}

.nav-btn {
width: 100%;
text-align: center;
}

.content-section {
padding: var(--spacing-md);
}

.section-title {
font-size: 2rem;
}

.subsection {
padding: var(--spacing-md);
}
}

@media (max-width: 480px) {
.header {
padding: var(--spacing-md);
}

.header h1 {
font-size: 2rem;
}

.section-title {
font-size: 1.8rem;
}
}

/* Animation stagger */
.subsection {
animation: fadeInStagger 0.6s ease-out both;
}

@keyframes fadeInStagger {
from {
opacity: 0;
transform: translateY(20px);
}
to {
opacity: 1;
transform: translateY(0);
}
}

.subsection:nth-child(1) { animation-delay: 0.1s; }
.subsection:nth-child(2) { animation-delay: 0.2s; }
.subsection:nth-child(3) { animation-delay: 0.3s; }
.subsection:nth-child(4) { animation-delay: 0.4s; }
.subsection:nth-child(5) { animation-delay: 0.5s; }
.subsection:nth-child(6) { animation-delay: 0.6s; }
.subsection:nth-child(7) { animation-delay: 0.7s; }
.subsection:nth-child(8) { animation-delay: 0.8s; }
</style>
</head>
<body>
<div class="container">
<div class="header">
<h1>üß¨ Vitamin-/Cofaktor-Defekte</h1>
<p>Komplett-Lerneinheit: Von Grundlagen bis Praxis</p>
<div class="progress-container">
<div class="progress-fill" id="progressBar" style="width: 0%"></div>
</div>
</div>

<div class="part-info">
<h3>üìö Vollst√§ndige Lerneinheit</h3>
<p>Diese Lerneinheit behandelt alle wichtigen Vitamin-/Cofaktor-Defekte umfassend: Grundlagen, Klinik, Diagnostik, Therapie und Praxis.</p>
</div>

<div class="navigation">
<button class="nav-btn active" onclick="showSection('biotinidase')">1. Biotinidase-Mangel</button>
<button class="nav-btn" onclick="showSection('carboxylase')">2. Multiple Carboxylase</button>
<button class="nav-btn" onclick="showSection('cobalamin')">3. Cobalamin-Defekte</button>
<button class="nav-btn" onclick="showSection('folsaeure')">4. Fols√§ure-Defekte</button>
<button class="nav-btn" onclick="showSection('quiz')">5. Lernkontrolle</button>
</div>

<!-- Biotinidase-Mangel -->
<div class="content-section active" id="biotinidase">
<h2 class="section-title">üî¨ Biotinidase-Mangel</h2>

<div class="subsection">
<h3>Grundlagen und Definition</h3>
<p><strong>Biotinidase-Mangel</strong> ist ein autosomal-rezessiver Defekt der Biotinidase (EC 3.5.1.12), die f√ºr das Recycling von Biotin aus biotinylierten Proteinen essentiell ist.</p>

<div class="highlight-box">
<h4>Epidemiologie und Vererbung</h4>
<ul>
<li><strong>Inzidenz:</strong> 1:60.000 - 1:137.000 (variiert regional)</li>
<li><strong>Tr√§gerfrequenz:</strong> 1:123 bis 1:185</li>
<li><strong>Vererbung:</strong> Autosomal-rezessiv</li>
<li><strong>Gen:</strong> BTD-Gen (Chromosom 3p25.1)</li>
<li><strong>Neugeborenenscreening:</strong> Seit 2005 in Deutschland</li>
</ul>
</div>

<table class="clinical-table">
<thead>
<tr>
<th>Schweregrad</th>
<th>Enzymaktivit√§t</th>
<th>Klinische Manifestation</th>
<th>Therapie</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Profund</strong></td>
<td>&lt;10% der Norm</td>
<td>Schwere Symptome ab 2-5 Monaten</td>
<td>Biotin 5-20 mg/d</td>
</tr>
<tr>
<td><strong>Partiell</strong></td>
<td>10-30% der Norm</td>
<td>Milde Symptome, oft asymptomatisch</td>
<td>Biotin 5-10 mg/d</td>
</tr>
<tr>
<td><strong>Atypisch</strong></td>
<td>Variable</td>
<td>Ungew√∂hnliche Pr√§sentation</td>
<td>Individuell angepasst</td>
</tr>
</tbody>
</table>
</div>

<div class="subsection">
<h3>Biochemie und Pathophysiologie</h3>

<div class="pathway-diagram">
<h4>Biotin-Recycling-Zyklus</h4>
<div style="display: flex; flex-direction: column; align-items: center; gap: 15px; margin: 20px 0;">
<div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
<div class="enzyme-box">Nahrungsproteine</div>
<span class="arrow">‚Üí</span>
<div class="enzyme-box">Biocytin/Biotinyl-Peptide</div>
<span class="arrow">‚Üí</span>
<div class="enzyme-box defect">Biotinidase</div>
<span class="arrow">‚Üí</span>
<div class="enzyme-box">Freies Biotin</div>
</div>
<div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center; margin-top: 20px;">
<div class="enzyme-box">Holocarboxylase-Synthetase</div>
<span class="arrow">‚Üê</span>
<div class="enzyme-box">Freies Biotin</div>
<span class="arrow">‚Üí</span>
<div class="enzyme-box">Biotinylierte Carboxylasen</div>
</div>
</div>
</div>

<div class="case-study">
<h4>üî¨ Betroffene Carboxylasen</h4>
<p><strong>Die vier biotinabh√§ngigen Carboxylasen:</strong></p>
<ul>
<li><strong>Acetyl-CoA-Carboxylase (ACC):</strong> Fetts√§uresynthese</li>
<li><strong>Propionyl-CoA-Carboxylase (PCC):</strong> Propionat-Metabolismus</li>
<li><strong>3-Methylcrotonyl-CoA-Carboxylase (MCC):</strong> Leucin-Abbau</li>
<li><strong>Pyruvat-Carboxylase (PC):</strong> Gluconeogenese, Anaplerotic Reaktionen</li>
</ul>

<p><strong>Konsequenzen bei Biotinmangel:</strong></p>
<ul>
<li>Akkumulation von organischen S√§uren (3-Methylcrotonyl-Glycin, 3-Hydroxyisovalerat)</li>
<li>St√∂rung der Gluconeogenese und Fetts√§uresynthese</li>
<li>Laktatazidose durch PC-Mangel</li>
<li>Hyperammon√§mie durch gest√∂rte N-Acetylglutamat-Synthese</li>
</ul>
</div>
</div>

<div class="subsection">
<h3>Klinisches Bild</h3>

<div class="highlight-box">
<h4>Fr√ºhsymptome (2-5 Monate)</h4>
<p><strong>Dermatologische Manifestationen:</strong></p>
<ul>
<li><strong>"Biotin-Rash":</strong> Perioraler, periokul√§rer schuppender Ausschlag</li>
<li><strong>Alopezie:</strong> Diffuser Haarausfall, auch Augenbrauen/Wimpern</li>
<li><strong>Candidose:</strong> Persistierende Windelsoor, orale Candidose</li>
<li><strong>Seborrhoische Dermatitis:</strong> Cradle cap, generalisiert</li>
</ul>

<p><strong>Neurologische Symptome:</strong></p>
<ul>
<li><strong>Krampfanf√§lle:</strong> Oft therapieresistent</li>
<li><strong>Hypotonie:</strong> Muskelschw√§che, schlechte Kopfkontrolle</li>
<li><strong>Entwicklungsr√ºckstand:</strong> Motorisch und kognitiv</li>
<li><strong>Ataxie:</strong> Gangunsicherheit bei √§lteren Kindern</li>
</ul>
</div>

<table class="clinical-table">
<thead>
<tr>
<th>Organsystem</th>
<th>Akute Symptome</th>
<th>Chronische Folgen</th>
<th>Reversibilit√§t</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Haut/Haare</strong></td>
<td>Erythemat√∂ser Ausschlag, Alopezie</td>
<td>Narbenbildung m√∂glich</td>
<td>Meist vollst√§ndig</td>
</tr>
<tr>
<td><strong>ZNS</strong></td>
<td>Krampfanf√§lle, Lethargie</td>
<td>Intellektuelle Behinderung</td>
<td>Partiell</td>
</tr>
<tr>
<td><strong>Auge</strong></td>
<td>Konjunktivitis</td>
<td>Optikusatrophie, Retinopathie</td>
<td>Irreversibel</td>
</tr>
<tr>
<td><strong>Ohr</strong></td>
<td>Otitis externa</td>
<td>Sensorineuraler H√∂rverlust</td>
<td>Irreversibel</td>
</tr>
<tr>
<td><strong>Immunsystem</strong></td>
<td>Rezidivierende Infekte</td>
<td>T-Zell-Defizienz</td>
<td>Meist reversibel</td>
</tr>
</tbody>
</table>

<div class="case-study">
<h4>üëÅÔ∏è Ophthalmologische Komplikationen</h4>
<p><strong>Irreversible Augensch√§den bei versp√§teter Diagnose:</strong></p>
<ul>
<li><strong>Optikusatrophie:</strong> Bleibende Visusminderung</li>
<li><strong>Retinale Pigmentver√§nderungen:</strong> "Salt-and-pepper" Fundus</li>
<li><strong>Katarakt:</strong> Fr√ºhzeitige Linsentr√ºbung</li>
<li><strong>Nystagmus:</strong> Oft als Erstmanifestation</li>
</ul>
<p><strong>Pr√§vention:</strong> Regelm√§√üige ophthalmologische Kontrollen auch bei behandelten Patienten</p>
</div>
</div>

<div class="subsection">
<h3>Diagnostik</h3>

<div class="diagnostic-flow">
<div class="flow-step">
<strong>Neugeborenenscreening</strong><br>
Biotinidase-Aktivit√§t im Trockenblut<br>
Cut-off: <30% der Norm
</div>
<div class="flow-arrow"></div>
<div class="flow-step">
<strong>Best√§tigungsdiagnostik</strong><br>
Quantitative Biotinidase-Aktivit√§t<br>
Organische S√§uren (Urin)
</div>
<div class="flow-arrow"></div>
<div class="flow-step">
<strong>Molekulargenetik</strong><br>
BTD-Genanalyse<br>
Familienschreening
</div>
</div>

<table class="clinical-table">
<thead>
<tr>
<th>Test</th>
<th>Normbereich</th>
<th>Biotinidase-Mangel</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Biotinidase-Aktivit√§t</strong></td>
<td>100% (5.9-18.2 nmol/min/ml)</td>
<td><10% (profund), 10-30% (partiell)</td>
<td>Definitive Diagnose</td>
</tr>
<tr>
<td><strong>3-Hydroxyisovalerat</strong></td>
<td><5 mmol/mol Kreatinin</td>
<td>50-500 mmol/mol Kreatinin</td>
<td>Sekund√§rer Biotin-Mangel</td>
</tr>
<tr>
<td><strong>3-Methylcrotonyl-Glycin</strong></td>
<td><15 mmol/mol Kreatinin</td>
<td>100-1000 mmol/mol Kreatinin</td>
<td>MCC-Defizienz</td>
</tr>
<tr>
<td><strong>Laktat</strong></td>
<td><2 mmol/l</td>
<td>2-8 mmol/l</td>
<td>PC-Defizienz</td>
</tr>
<tr>
<td><strong>Biotin (Plasma)</strong></td>
<td>200-1000 ng/l</td>
<td>Meist normal</td>
<td>Recycling-Defekt!</td>
</tr>
</tbody>
</table>

<div class="highlight-box">
<h4>Molekulargenetik - H√§ufige Mutationen</h4>
<p><strong>Europ√§ische Population:</strong></p>
<ul>
<li><strong>c.1330G>C (p.Asp444His):</strong> H√§ufigste Mutation (50-60%)</li>
<li><strong>c.98_104delinsTCC:</strong> Zweith√§ufigste (15-20%)</li>
<li><strong>c.1612C>T (p.Arg538Cys):</strong> Milde Form</li>
</ul>

<p><strong>Genotyp-Ph√§notyp-Korrelation:</strong></p>
<ul>
<li><strong>Null-Mutationen:</strong> Profunde Form, schwere Symptome</li>
<li><strong>Missense-Mutationen:</strong> Variable Restaktivit√§t, mildere Verl√§ufe</li>
<li><strong>Founder-Effekte:</strong> Regionale H√§ufungen bestimmter Mutationen</li>
</ul>
</div>
</div>

<div class="subsection">
<h3>Therapie</h3>

<div class="case-study">
<h4>üíä Biotin-Substitution</h4>
<p><strong>Dosierung:</strong></p>
<ul>
<li><strong>Profunder Mangel:</strong> 5-20 mg/d oral (Kinder), bis 40 mg/d (Erwachsene)</li>
<li><strong>Partieller Mangel:</strong> 5-10 mg/d</li>
<li><strong>Erhaltungstherapie:</strong> Niedrigste effektive Dosis</li>
<li><strong>Stresszeiten:</strong> Dosiserh√∂hung bei Infekten/Operationen</li>
</ul>

<p><strong>Praktische Aspekte:</strong></p>
<ul>
<li><strong>Galenik:</strong> Tabletten, Kapseln, L√∂sungen verf√ºgbar</li>
<li><strong>Zeitpunkt:</strong> Unabh√§ngig von Mahlzeiten</li>
<li><strong>Compliance:</strong> Lebenslange Therapie erforderlich</li>
<li><strong>√úberdosierung:</strong> Praktisch unm√∂glich (wasserl√∂slich)</li>
</ul>
</div>

<table class="clinical-table">
<thead>
<tr>
<th>Symptom</th>
<th>Ansprechen auf Biotin</th>
<th>Zeitrahmen</th>
<th>Irreversibilit√§t</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dermatitis</strong></td>
<td>Exzellent</td>
<td>1-2 Wochen</td>
<td>Nein</td>
</tr>
<tr>
<td><strong>Alopezie</strong></td>
<td>Sehr gut</td>
<td>2-6 Monate</td>
<td>Nein</td>
</tr>
<tr>
<td><strong>Krampfanf√§lle</strong></td>
<td>Gut</td>
<td>Tage bis Wochen</td>
<td>Selten</td>
</tr>
<tr>
<td><strong>Entwicklungsr√ºckstand</strong></td>
<td>Variabel</td>
<td>Monate bis Jahre</td>
<td>M√∂glich</td>
</tr>
<tr>
<td><strong>H√∂rverlust</strong></td>
<td>Schlecht</td>
<td>-</td>
<td>Meist</td>
</tr>
<tr>
<td><strong>Optikusatrophie</strong></td>
<td>Schlecht</td>
<td>-</td>
<td>Meist</td>
</tr>
</tbody>
</table>

<div class="highlight-box">
<h4>Monitoring und Verlaufskontrollen</h4>
<p><strong>Regelm√§√üige Kontrollen:</strong></p>
<ul>
<li><strong>Biotinidase-Aktivit√§t:</strong> J√§hrlich (Compliance-Check)</li>
<li><strong>Organische S√§uren:</strong> 6-12 monatlich</li>
<li><strong>Ophthalmologie:</strong> J√§hrlich (Funduskopie, Visus)</li>
<li><strong>Audiologie:</strong> J√§hrlich (H√∂rtests)</li>
<li><strong>Entwicklung:</strong> Halbj√§hrlich bis zum Schulalter</li>
</ul>

<p><strong>Prognose:</strong></p>
<ul>
<li><strong>Neugeborenenscreening:</strong> Exzellente Prognose bei pr√§symptomatischer Therapie</li>
<li><strong>Fr√ºhe Diagnose:</strong> Meist normale Entwicklung</li>
<li><strong>Sp√§te Diagnose:</strong> Irreversible neurologische/sensorische Defekte m√∂glich</li>
</ul>
</div>
</div>

<div class="next-step">
<button class="next-btn" onclick="showSection('carboxylase')">Weiter zu Multiple Carboxylase-Defizienz ‚Üí</button>
</div>
</div>

<!-- Multiple Carboxylase-Defizienz -->
<div class="content-section" id="carboxylase">
<h2 class="section-title">üîó Multiple Carboxylase-Defizienz</h2>

<div class="subsection">
<h3>Grundlagen und Klassifikation</h3>

<p><strong>Multiple Carboxylase-Defizienz</strong> umfasst zwei genetisch distinkte St√∂rungen der Biotin-Verwertung, die zu einem funktionellen Mangel aller vier biotinabh√§ngigen Carboxylasen f√ºhren.</p>

<table class="clinical-table">
<thead>
<tr>
<th>Typ</th>
<th>Enzymdefekt</th>
<th>Gen</th>
<th>Manifestationsalter</th>
<th>Biotin-Ansprechen</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fr√ºhe Form</strong></td>
<td>Holocarboxylase-Synthetase (HCS)</td>
<td>HLCS (21q22.13)</td>
<td>Neonatal (0-1 Monat)</td>
<td>Variabel</td>
</tr>
<tr>
<td><strong>Sp√§te Form</strong></td>
<td>Biotinidase</td>
<td>BTD (3p25.1)</td>
<td>2-24 Monate</td>
<td>Exzellent</td>
</tr>
</tbody>
</table>

<div class="pathway-diagram">
<h4>Biotin-Cofaktor-Zyklus</h4>
<div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin: 20px 0;">
<div style="text-align: center;">
<h5 style="color: #dc2626; margin-bottom: 15px;">üî¥ Holocarboxylase-Synthetase-Mangel</h5>
<div class="enzyme-box defect">HCS ‚Üì</div>
<div class="arrow" style="transform: rotate(90deg); color: #dc2626;">‚Üì</div>
<div class="metabolite-box" style="background: linear-gradient(135deg, #dc2626, #b91c1c);">Apo-Carboxylasen ‚Üë</div>
<div class="arrow" style="transform: rotate(90deg); color: #dc2626;">‚Üì</div>
<div class="metabolite-box" style="background: linear-gradient(135deg, #b91c1c, #991b1b);">Funktionelle Carboxylase-Aktivit√§t ‚Üì‚Üì</div>
</div>
<div style="text-align: center;">
<h5 style="color: #ea580c; margin-bottom: 15px;">üü† Biotinidase-Mangel</h5>
<div class="enzyme-box defect">Biotinidase ‚Üì</div>
<div class="arrow" style="transform: rotate(90deg); color: #ea580c;">‚Üì</div>
<div class="metabolite-box" style="background: linear-gradient(135deg, #ea580c, #dc2626);">Biotin-Recycling ‚Üì</div>
<div class="arrow" style="transform: rotate(90deg); color: #ea580c;">‚Üì</div>
<div class="metabolite-box" style="background: linear-gradient(135deg, #dc2626, #b91c1c);">Sekund√§rer Biotin-Mangel</div>
</div>
</div>
</div>
</div>

<div class="subsection">
<h3>Holocarboxylase-Synthetase-Mangel (Fr√ºhe Form)</h3>

<div class="case-study">
<h4>üçº Neonatale Pr√§sentation</h4>
<p><strong>Typischer Verlauf:</strong></p>
<ul>
<li><strong>Manifestation:</strong> Erste Lebenstage bis 6 Wochen</li>
<li><strong>Initialsymptome:</strong> Trinkschw√§che, Erbrechen, Lethargie</li>
<li><strong>Progression:</strong> Rapid progredient ohne Therapie</li>
<li><strong>Outcome unbehandelt:</strong> Meist letal</li>
</ul>

<p><strong>Klinische Zeichen:</strong></p>
<ul>
<li><strong>Metabolische Azidose:</strong> Schwer, oft pH <7,2</li>
<li><strong>Hyperammon√§mie:</strong> 200-800 Œºmol/l</li>
<li><strong>Laktatazidose:</strong> Laktat >5 mmol/l</li>
<li><strong>Ketonurie:</strong> Ausgepr√§gt</li>
<li><strong>Charakteristischer Geruch:</strong> "Katzenurin-√§hnlich"</li>
</ul>
</div>

<div class="highlight-box">
<h4>Biochemische Marker</h4>
<p><strong>Organische S√§uren (sehr charakteristisch):</strong></p>
<ul>
<li><strong>3-Methylcrotonyl-Glycin:</strong> Massiv erh√∂ht (>1000x)</li>
<li><strong>3-Hydroxyisovalerat:</strong> Stark erh√∂ht</li>
<li><strong>3-Hydroxypropinat:</strong> Erh√∂ht</li>
<li><strong>Methylcitrats√§ure:</strong> Erh√∂ht</li>
<li><strong>Lactat:</strong> Sekund√§r erh√∂ht</li>
<li><strong>3-Hydroxybutterat:</strong> Ketonk√∂rper ‚Üë</li>
</ul>
</div>

<table class="clinical-table">
<thead>
<tr>
<th>Carboxylase</th>
<th>Substrat-Akkumulation</th>
<th>Urin-Marker</th>
<th>Klinische Relevanz</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>3-Methylcrotonyl-CoA-Carboxylase</strong></td>
<td>3-Methylcrotonyl-CoA</td>
<td>3-Methylcrotonyl-Glycin, 3-Hydroxyisovalerat</td>
<td>Leucin-Intoleranz</td>
</tr>
<tr>
<td><strong>Propionyl-CoA-Carboxylase</strong></td>
<td>Propionyl-CoA</td>
<td>3-Hydroxypropinat, Methylcitrat</td>
<td>Protein-Intoleranz</td>
</tr>
<tr>
<td><strong>Pyruvat-Carboxylase</strong></td>
<td>Pyruvat</td>
<td>Laktat, Pyruvat</td>
<td>Hypoglyk√§mie, Azidose</td>
</tr>
<tr>
<td><strong>Acetyl-CoA-Carboxylase</strong></td>
<td>Acetyl-CoA</td>
<td>Keine spezifischen</td>
<td>Fetts√§uresynthese ‚Üì</td>
</tr>
</tbody>
</table>
</div>

<div class="subsection">
<h3>Genetik und Molekularbiologie</h3>

<div class="pathway-diagram">
<h4>HLCS-Gen und Enzymfunktion</h4>
<div style="background: #f8fafc; padding: 20px; border-radius: 10px; margin: 20px 0;">
<p><strong>Holocarboxylase-Synthetase:</strong></p>
<ul>
<li><strong>Funktion:</strong> Kovalente Bindung von Biotin an Carboxylasen</li>
<li><strong>Km f√ºr Biotin:</strong> Normal 0,1-1 ŒºM</li>
<li><strong>Bei Mutationen:</strong> Erh√∂hte Km (bis 100-1000x)</li>
<li><strong>Therapeutische Konsequenz:</strong> Hohe Biotin-Dosen n√∂tig</li>
</ul>
</div>
</div>

<div class="case-study">
<h4>üß¨ H√§ufige HLCS-Mutationen</h4>
<p><strong>Schwere Formen (Biotin-resistent):</strong></p>
<ul>
<li><strong>c.1411C>T (p.Leu471Pro):</strong> Null-Mutation</li>
<li><strong>c.1522C>T (p.Arg508Trp):</strong> Strukturdefekt</li>
<li><strong>c.1368_1371delACAG:</strong> Frameshift</li>
</ul>

<p><strong>Milde Formen (Biotin-responsiv):</strong></p>
<ul>
<li><strong>c.1067A>G (p.Asn356Ser):</strong> Erh√∂hte Km</li>
<li><strong>c.1540G>A (p.Val514Met):</strong> Reduzierte Affinit√§t</li>
<li><strong>c.1119C>A (p.Asp373Glu):</strong> Temperatur-sensitiv</li>
</ul>
</div>
</div>

<div class="subsection">
<h3>Diagnostisches Vorgehen</h3>

<div class="diagnostic-flow">
<div class="flow-step">
<strong>Verdacht bei Neugeborenem</strong><br>
Azidose + Hyperammon√§mie<br>
+ Ketonurie
</div>
<div class="flow-arrow"></div>
<div class="flow-step">
<strong>Organische S√§uren</strong><br>
Charakteristisches Muster<br>
3-Methylcrotonyl-Glycin ‚Üë‚Üë
</div>
<div class="flow-arrow"></div>
<div class="flow-step">
<strong>Biotin-Test</strong><br>
Empirische Therapie<br>
Klinisches Ansprechen
</div>
<div class="flow-arrow"></div>
<div class="flow-step">
<strong>Differenzierung</strong><br>
Biotinidase vs. HCS<br>
Enzymaktivit√§t/Genetik
</div>
</div>

<div class="highlight-box">
<h4>Differentialdiagnose der organischen Azid√§mien</h4>
<table class="clinical-table" style="margin: 0;">
<thead>
<tr>
<th>Erkrankung</th>
<th>Schl√ºssel-Metabolit</th>
<th>Biotin-Ansprechen</th>
<th>Manifestationsalter</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HCS-Mangel</strong></td>
<td>3-Methylcrotonyl-Glycin</td>
<td>Variable</td>
<td>Neonatal</td>
</tr>
<tr>
<td><strong>Biotinidase-Mangel</strong></td>
<td>3-Methylcrotonyl-Glycin</td>
<td>Exzellent</td>
<td>2-24 Monate</td>
</tr>
<tr>
<td><strong>Propionazid√§mie</strong></td>
<td>3-Hydroxypropinat</td>
<td>Nein</td>
<td>Neonatal/infantil</td>
</tr>
<tr>
<td><strong>Methylmalonazid√§mie</strong></td>
<td>Methylmalonat</td>
<td>Nur cblA/B</td>
<td>Neonatal/infantil</td>
</tr>
<tr>
<td><strong>Isovaleriazid√§mie</strong></td>
<td>Isovaleryl-Glycin</td>
<td>Nein</td>
<td>Neonatal/infantil</td>
</tr>
</tbody>
</table>
</div>
</div>

<div class="subsection">
<h3>Therapie der Multiple Carboxylase-Defizienz</h3>

<div class="case-study">
<h4>üíä Akuttherapie</h4>
<p><strong>Notfallmanagement:</strong></p>
<ul>
<li><strong>Biotin sofort:</strong> 10-40 mg/d i.v. oder oral</li>
<li><strong>Azidose-Korrektur:</strong> NaHCO‚ÇÉ vorsichtig titrieren</li>
<li><strong>Hyperammon√§mie:</strong> Protein-Stopp, ggf. Dialyse</li>
<li><strong>Fl√ºssigkeit/Elektrolyte:</strong> Ausgleich der Verluste</li>
<li><strong>Monitoring:</strong> BGA, NH‚ÇÉ, Laktat alle 4-6h</li>
</ul>

<p><strong>Klinisches Ansprechen:</strong></p>
<ul>
<li><strong>Biochemisch:</strong> Normalisierung in 24-72h</li>
<li><strong>Klinisch:</strong> Besserung in 2-7 Tagen</li>
<li><strong>Organische S√§uren:</strong> R√ºckgang in 1-2 Wochen</li>
</ul>
</div>

<table class="clinical-table">
<thead>
<tr>
<th>Therapies√§ule</th>
<th>HCS-Mangel</th>
<th>Biotinidase-Mangel</th>
<th>√úberwachung</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Biotin-Dosierung</strong></td>
<td>10-100 mg/d (sehr variabel)</td>
<td>5-20 mg/d</td>
<td>Organische S√§uren</td>
</tr>
<tr>
<td><strong>Protein-Restriktion</strong></td>
<td>Manchmal erforderlich</td>
<td>Nicht n√∂tig</td>
<td>Ammoniak, Wachstum</td>
</tr>
<tr>
<td><strong>Leucin-Restriktion</strong></td>
<td>Bei schweren Formen</td>
<td>Nicht n√∂tig</td>
<td>3-Methylcrotonyl-Glycin</td>
</tr>
<tr>
<td><strong>Notfallregime</strong></td>
<td>Bei Dekompensation</td>
<td>Meist nicht n√∂tig</td>
<td>Klinik, Labor</td>
</tr>
</tbody>
</table>

<div class="highlight-box">
<h4>Langzeitprognose</h4>
<p><strong>HCS-Mangel:</strong></p>
<ul>
<li><strong>Biotin-responsive Formen:</strong> Normale Entwicklung m√∂glich</li>
<li><strong>Biotin-resistente Formen:</strong> Oft intellektuelle Behinderung</li>
<li><strong>Compliance crucial:</strong> Strikte Biotin-Einnahme lebenslang</li>
</ul>

<p><strong>Biotinidase-Mangel:</strong></p>
<ul>
<li><strong>Exzellente Prognose:</strong> Bei fr√ºher Diagnose/Therapie</li>
<li><strong>Vollst√§ndige Reversibilit√§t:</strong> Der meisten Symptome</li>
<li><strong>Ausnahmen:</strong> Optikus-/H√∂rnervensch√§den</li>
</ul>
</div>
</div>

<div class="next-step">
<button class="next-btn" onclick="showSection('cobalamin')">Weiter zu Cobalamin-Defekten ‚Üí</button>
</div>
</div>

<!-- Cobalamin-Defekte -->
<div class="content-section" id="cobalamin">
<h2 class="section-title">üî¥ Cobalamin-Defekte</h2>

<div class="subsection">
<h3>√úbersicht und Klassifikation</h3>

<p><strong>Cobalamin (Vitamin B‚ÇÅ‚ÇÇ)-Defekte</strong> umfassen eine heterogene Gruppe von St√∂rungen der Vitamin B‚ÇÅ‚ÇÇ-Aufnahme, des Transports oder der intrazellul√§ren Verarbeitung zu den aktiven Cofaktoren Methylcobalamin und Adenosylcobalamin.</p>

<table class="clinical-table">
<thead>
<tr>
<th>Defekt-Typ</th>
<th>Gen</th>
<th>Betroffene Reaktion</th>
<th>Hauptmetabolit</th>
<th>Manifestation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>cblA</strong></td>
<td>MMAA</td>
<td>AdoCbl-Synthese</td>
<td>Methylmalonat</td>
<td>Methylmalonazid√§mie</td>
</tr>
<tr>
<td><strong>cblB</strong></td>
<td>MMAB</td>
<td>AdoCbl-Synthese</td>
<td>Methylmalonat</td>
<td>Methylmalonazid√§mie</td>
</tr>
<tr>
<td><strong>cblC</strong></td>
<td>MMACHC</td>
<td>Cbl-Processing</td>
<td>MMA + Homocystein</td>
<td>Kombiniert</td>
</tr>
<tr>
<td><strong>cblD</strong></td>
<td>MMADHC</td>
<td>Cofaktor-Verteilung</td>
<td>Variable</td>
<td>Variable</td>
</tr>
<tr>
<td><strong>cblE</strong></td>
<td>MTRR</td>
<td>MeCbl-Regeneration</td>
<td>Homocystein</td>
<td>Homocystinurie</td>
</tr>
<tr>
<td><strong>cblF</strong></td>
<td>LMBRD1</td>
<td>Lysosomaler Export</td>
<td>MMA + Homocystein</td>
<td>Kombiniert</td>
</tr>
<tr>
<td><strong>cblG</strong></td>
<td>MTR</td>
<td>Methionin-Synthase</td>
<td>Homocystein</td>
<td>Homocystinurie</td>
</tr>
</tbody>
</table>

<div class="pathway-diagram">
<h4>Intrazellul√§rer Cobalamin-Metabolismus</h4>
<div style="background: linear-gradient(90deg, #f3f4f6 50%, #e5e7eb 50%); padding: 20px; border-radius: 10px; margin: 20px 0;">
<div style="text-align: center; margin-bottom: 15px;">
<span style="margin-right: 50px; font-weight: bold;">Cytosol</span>
<span style="font-weight: bold;">Mitochondrium</span>
</div>

<div style="display: flex; flex-direction: column; gap: 15px;">
<div style="display: flex; align-items: center; justify-content: center; flex-wrap: wrap; gap: 10px;">
<div class="enzyme-box">OH-Cbl/CN-Cbl</div>
<span class="arrow">‚Üí</span>
<div class="enzyme-box" style="background: linear-gradient(135deg, #dc2626, #b91c1c);">cblC (MMACHC)</div>
<span class="arrow">‚Üí</span>
<div class="enzyme-box">Cob(II)alamin</div>
</div>

<div style="display: flex; align-items: center; justify-content: space-around; flex-wrap: wrap; gap: 10px; margin: 20px 0;">
<div style="text-align: center;">
<div class="enzyme-box" style="background: linear-gradient(135deg, #7c3aed, #6d28d9);">cblE (MTRR)</div>
<div class="arrow" style="transform: rotate(90deg);">‚Üì</div>
<div class="enzyme-box">Methylcobalamin</div>
<div class="arrow" style="transform: rotate(90deg);">‚Üì</div>
<div class="enzyme-box" style="background: linear-gradient(135deg, #2563eb, #1d4ed8);">Methionin-Synthase</div>
</div>

<div style="text-align: center;">
<div class="enzyme-box" style="background: linear-gradient(135deg, #ea580c, #dc2626);">cblA/B</div>
<div class="arrow" style="transform: rotate(90deg);">‚Üì</div>
<div class="enzyme-box">Adenosylcobalamin</div>
<div class="arrow" style="transform: rotate(90deg);">‚Üì</div>
<div class="enzyme-box" style="background: linear-gradient(135deg, #16a34a, #15803d);">Methylmalonyl-CoA-Mutase</div>
</div>
</div>
</div>
</div>
</div>
</div>

<div class="subsection">
<h3>cblC-Defekt (h√§ufigste Form)</h3>

<div class="case-study">
<h4>üî¨ MMACHC-Gen und Pathophysiologie</h4>
<p><strong>Molekulare Basis:</strong></p>
<ul>
<li><strong>Enzym:</strong> Methylmalonic aciduria and homocystinuria type C protein</li>
<li><strong>Funktion:</strong> Decyanierung und Reduktion von Cobalamin</li>
<li><strong>Lokalisation:</strong> Cytosol</li>
<li><strong>Konsequenz:</strong> St√∂rung beider Cobalamin-Cofaktor-Wege</li>
</ul>

<p><strong>Biochemische Folgen:</strong></p>
<ul>
<li><strong>Methylmalonyl-CoA-Mutase-Mangel:</strong> Methylmalonat ‚Üë</li>
<li><strong>Methionin-Synthase-Mangel:</strong> Homocystein ‚Üë, Methionin ‚Üì</li>
<li><strong>Folat-Trap:</strong> 5-Methyltetrahydrofolat akkumuliert</li>
<li><strong>S-Adenosylmethionin ‚Üì:</strong> Methylierungsdefekte</li>
</ul>
</div>

<div class="highlight-box">
<h4>Klinische Ph√§notypen</h4>
<p><strong>Fr√ºhe Form (neonatal/infantil):</strong></p>
<ul>
<li><strong>Manifestation:</strong> Erste Lebenswochen bis 2 Jahre</li>
<li><strong>Symptome:</strong> Gedeihst√∂rung, Entwicklungsr√ºckstand, Megaloblastenan√§mie</li>
<li><strong>Schwere:</strong> Oft schwer, Multiorgan-Beteiligung</li>
<li><strong>Ansprechen:</strong> Gut auf OH-Cbl</li>
</ul>

<p><strong>Sp√§te Form (juvenil/adult):</strong></p>
<ul>
<li><strong>Manifestation:</strong> Adoleszenz bis Erwachsenenalter</li>
<li><strong>Symptome:</strong> Neurologisch-psychiatrisch dominiert</li>
<li><strong>Besonderheit:</strong> Oft fehlende h√§matologische Zeichen</li>
<li><strong>Prognose:</strong> Variable, oft progredient</li>
</ul>
</div>

<table class="clinical-table">
<thead>
<tr>
<th>Organsystem</th>
<th>Fr√ºhe Form</th>
<th>Sp√§te Form</th>
<th>Pathomechanismus</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>H√§matologisch</strong></td>
<td>Megaloblastenan√§mie, Panzytopenie</td>
<td>Oft normal</td>
<td>DNA-Synthese-St√∂rung</td>
</tr>
<tr>
<td><strong>Neurologisch</strong></td>
<td>Entwicklungsr√ºckstand, Krampfanf√§lle</td>
<td>Demenz, Neuropathie, Myelopathie</td>
<td>Methylierung ‚Üì</td>
</tr>
<tr>
<td><strong>Ophthalmologisch</strong></td>
<td>Makul√§re Degeneration</td>
<td>Retinitis pigmentosa</td>
<td>Unbekannt</td>
</tr>
<tr>
<td><strong>Renal</strong></td>
<td>Seltener</td>
<td>Chronische Niereninsuffizienz</td>
<td>Vaskul√§re Sch√§den</td>
</tr>
<tr>
<td><strong>Kardiovaskul√§r</strong></td>
<td>Kardiomyopathie</td>
<td>Thromboembolien</td>
<td>Hyperhomocystein√§mie</td>
</tr>
</tbody>
</table>
</div>

<div class="subsection">
<h3>Diagnostik der Cobalamin-Defekte</h3>

<div class="diagnostic-flow">
<div class="flow-step">
<strong>Verdacht</strong><br>
MMA ‚Üë und/oder<br>
Homocystein ‚Üë
</div>
<div class="flow-arrow"></div>
<div class="flow-step">
<strong>Basislabor</strong><br>
Cobalamin, Folat<br>
Methylmalonat, Homocystein
</div>
<div class="flow-arrow"></div>
<div class="flow-step">
<strong>Differenzierung</strong><br>
Nur MMA ‚Üë vs.<br>
MMA + Homocystein ‚Üë
</div>
<div class="flow-arrow"></div>
<div class="flow-step">
<strong>Molekulargenetik</strong><br>
Targeted Panel<br>
Funktionstest
</div>
</div>

<table class="clinical-table">
<thead>
<tr>
<th>Parameter</th>
<th>Normbereich</th>
<th>cblC-Defekt</th>
<th>Differentialdiagnose</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Methylmalonat (Urin)</strong></td>
<td><5 mmol/mol Kreatinin</td>
<td>100-5000 mmol/mol</td>
<td>MMA, cblA/B</td>
</tr>
<tr>
<td><strong>Homocystein (Plasma)</strong></td>
<td><15 Œºmol/l</td>
<td>50-500 Œºmol/l</td>
<td>CBS, cblE/G</td>
</tr>
<tr>
<td><strong>Methionin (Plasma)</strong></td>
<td>15-40 Œºmol/l</td>
<td>5-15 Œºmol/l</td>
<td>Charakteristisch niedrig</td>
</tr>
<tr>
<td><strong>Cobalamin (Serum)</strong></td>
<td>200-900 pmol/l</td>
<td>Meist normal</td>
<td>Funktioneller Mangel!</td>
</tr>
<tr>
<td><strong>Propionylcarnitin (C3)</strong></td>
<td><5 Œºmol/l</td>
<td>10-50 Œºmol/l</td>
<td>Sekund√§r durch MMA</td>
</tr>
</tbody>
</table>

<div class="case-study">
<h4>üß™ Funktionsdiagnostik</h4>
<p><strong>Cobalamin-Stimulationstest:</strong></p>
<ul>
<li><strong>Prinzip:</strong> OH-Cobalamin 1-2 mg/d f√ºr 3 Tage</li>
<li><strong>Messparameter:</strong> MMA und Homocystein vor/nach</li>
<li><strong>Erwartung:</strong> Deutlicher Abfall bei responsiven Formen</li>
<li><strong>Interpretation:</strong> Hilft bei Genotyp-Ph√§notyp-Korrelation</li>
</ul>

<p><strong>Fibroblasten-Komplementationstest:</strong></p>
<ul>
<li><strong>Methode:</strong> Zellfusion mit bekannten Kontrollzellen</li>
<li><strong>Endpunkt:</strong> Propionat-Inkorporation</li>
<li><strong>Anwendung:</strong> Bei unklaren genetischen Befunden</li>
<li><strong>Limitationen:</strong> Aufw√§ndig, nur in Speziallabors</li>
</ul>
</div>
</div>

<div class="subsection">
<h3>Therapie der Cobalamin-Defekte</h3>

<div class="case-study">
<h4>üíä cblC-Defekt Therapie</h4>
<p><strong>Hydroxocobalamin (OH-Cbl):</strong></p>
<ul>
<li><strong>Dosierung:</strong> 1-2 mg/d i.m. oder subkutan</li>
<li><strong>Frequenz:</strong> T√§glich bis w√∂chentlich (je nach Ansprechen)</li>
<li><strong>Monitoring:</strong> MMA, Homocystein, Methionin</li>
<li><strong>Ziel:</strong> Normalisierung oder maximale Reduktion</li>
</ul>

<p><strong>Fols√§ure-Supplementation:</strong></p>
<ul>
<li><strong>Dosierung:</strong> 5-15 mg/d oral</li>
<li><strong>Rationale:</strong> Kompensation des Folat-Traps</li>
<li><strong>Cave:</strong> Nicht als Monotherapie (maskiert B‚ÇÅ‚ÇÇ-Mangel)</li>
</ul>

<p><strong>Betain (Trimethylglycin):</strong></p>
<ul>
<li><strong>Dosierung:</strong> 100-250 mg/kg/d in 2-3 Dosen</li>
<li><strong>Mechanismus:</strong> Alternative Methylierung von Homocystein</li>
<li><strong>Vorteil:</strong> Unabh√§ngig von Cobalamin-Status</li>
<li><strong>Monitoring:</strong> Methionin (√úberdosierung vermeiden)</li>
</ul>
</div>

<table class="clinical-table">
<thead>
<tr>
<th>Defekt-Typ</th>
<th>Prim√§rtherapie</th>
<th>Zusatztherapie</th>
<th>Ansprechen</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>cblA/B</strong></td>
<td>OH-Cobalamin 1-2 mg/d</td>
<td>Carnitin bei Bedarf</td>
<td>Meist excellent</td>
</tr>
<tr>
<td><strong>cblC fr√ºh</strong></td>
<td>OH-Cobalamin 1-2 mg/d</td>
<td>Fols√§ure, Betain</td>
<td>Gut</td>
</tr>
<tr>
<td><strong>cblC sp√§t</strong></td>
<td>OH-Cobalamin 2-5 mg/d</td>
<td>Fols√§ure, Betain</td>
<td>Variabel</td>
</tr>
<tr>
<td><strong>cblE/G</strong></td>
<td>OH-Cobalamin ¬± Betain</td>
<td>Fols√§ure</td>
<td>Meist gut</td>
</tr>
</tbody>
</table>

<div class="highlight-box">
<h4>Langzeit-Monitoring</h4>
<p><strong>Biochemisch (alle 3-6 Monate):</strong></p>
<ul>
<li><strong>Methylmalonat (Urin):</strong> Ziel <100 mmol/mol Kreatinin</li>
<li><strong>Homocystein (Plasma):</strong> Ziel <50 Œºmol/l</li>
<li><strong>Methionin (Plasma):</strong> Ziel >20 Œºmol/l</li>
<li><strong>Folat, B‚ÇÅ‚ÇÇ:</strong> Ausreichende Versorgung sicherstellen</li>
</ul>

<p><strong>Klinisch (j√§hrlich):</strong></p>
<ul>
<li><strong>Ophthalmologie:</strong> Makuladegeneration, Retinopathie</li>
<li><strong>Neurologie:</strong> Entwicklung, periphere Neuropathie</li>
<li><strong>Nephrologie:</strong> Nierenfunktion (bei sp√§ten Formen)</li>
<li><strong>H√§matologie:</strong> Blutbild, B‚ÇÅ‚ÇÇ-Status</li>
</ul>
</div>
</div>

<div class="next-step">
<button class="next-btn" onclick="showSection('folsaeure')">Weiter zu Fols√§ure-Defekten ‚Üí</button>
</div>
</div>

<!-- Fols√§ure-Defekte -->
<div class="content-section" id="folsaeure">
<h2 class="section-title">üçÉ Fols√§ure-Transporter-Defekte</h2>

<div class="subsection">
<h3>Grundlagen der Folat-Hom√∂ostase</h3>

<p><strong>Folat-Transporter-Defekte</strong> umfassen seltene St√∂rungen des Fols√§ure-Transports und -Metabolismus, die zu einem funktionellen intrazellul√§ren Folatmangel trotz oft normaler Serumspiegel f√ºhren.</p>

<div class="pathway-diagram">
<h4>Folat-Transport und -Metabolismus</h4>
<div style="background: linear-gradient(135deg, #f0fdf4, #dcfce7); padding: 20px; border-radius: 10px; margin: 20px 0; border: 2px solid #22c55e;">
<div style="display: grid; grid-template-columns: 1fr 2fr 1fr; gap: 20px; align-items: center;">
<div style="text-align: center;">
<h5 style="color: #166534; margin-bottom: 10px;">Aufnahme</h5>
<div class="enzyme-box" style="background: linear-gradient(135deg, #22c55e, #16a34a);">RFC1</div>
<div style="font-size: 0.9em; margin-top: 5px;">Reduced Folate Carrier</div>
</div>
<div style="text-align: center;">
<h5 style="color: #166534; margin-bottom: 10px;">ZNS-Transport</h5>
<div class="enzyme-box" style="background: linear-gradient(135deg, #dc2626, #b91c1c);">FOLR1</div>
<div style="font-size: 0.9em; margin-top: 5px;">Folat-Rezeptor Œ±</div>
<div class="arrow" style="margin: 10px;">‚Üì</div>
<div class="enzyme-box defect">PCFT</div>
<div style="font-size: 0.9em; margin-top: 5px;">Proton-coupled Folate Transporter</div>
</div>
<div style="text-align: center;">
<h5 style="color: #166534; margin-bottom: 10px;">Recycling</h5>
<div class="enzyme-box" style="background: linear-gradient(135deg, #7c3aed, #6d28d9);">DHFR</div>
<div style="font-size: 0.9em; margin-top: 5px;">Dihydrofolat-Reduktase</div>
</div>
</div>
</div>
</div>

<table class="clinical-table">
<thead>
<tr>
<th>Defekt</th>
<th>Gen</th>
<th>Protein</th>
<th>Hauptsymptome</th>
<th>Serum-Folat</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CFD</strong></td>
<td>FOLR1</td>
<td>Folat-Rezeptor Œ±</td>
<td>Zerebrale Folat-Defizienz</td>
<td>Normal</td>
</tr>
<tr>
<td><strong>PCFT-Mangel</strong></td>
<td>SLC46A1</td>
<td>Proton-coupled Folate Transporter</td>
<td>Megaloblastenan√§mie + ZNS</td>
<td>Niedrig</td>
</tr>
<tr>
<td><strong>DHFR-Mangel</strong></td>
<td>DHFR</td>
<td>Dihydrofolat-Reduktase</td>
<td>Megaloblastose + Immundefekt</td>
<td>Variabel</td>
</tr>
<tr>
<td><strong>RFC1-Mangel</strong></td>
<td>SLC19A1</td>
<td>Reduced Folate Carrier</td>
<td>Sehr selten</td>
<td>Hoch</td>
</tr>
</tbody>
</table>
</div>

<div class="subsection">
<h3>Zerebrale Folat-Defizienz (CFD)</h3>

<div class="case-study">
<h4>üß† Pathophysiologie und Klinik</h4>
<p><strong>Molekulare Basis:</strong></p>
<ul>
<li><strong>Defekt:</strong> Folat-Rezeptor Œ± (FOLR1) an Blut-Hirn-Schranke</li>
<li><strong>Konsequenz:</strong> Gest√∂rter Folat-Transport ins ZNS</li>
<li><strong>Besonderheit:</strong> Systemische Folat-Hom√∂ostase intakt</li>
<li><strong>CSF-Folat:</strong> Typisch <10 nmol/l (Normal >40 nmol/l)</li>
</ul>

<p><strong>Klinische Manifestation:</strong></p>
<ul>
<li><strong>Beginn:</strong> Meist 6-24 Monate</li>
<li><strong>Initialsymptome:</strong> Entwicklungsr√ºckstand, Reizbarkeit</li>
<li><strong>Progression:</strong> Epilepsie, spastische Tetraparese</li>
<li><strong>Besonderheit:</strong> Normale h√§matologische Parameter</li>
</ul>
</div>

<div class="highlight-box">
<h4>Klassische Symptom-Trias</h4>
<ul>
<li><strong>1. Entwicklungsr√ºckstand:</strong> Verlust erworbener F√§higkeiten</li>
<li><strong>2. Bewegungsst√∂rung:</strong> Spastik, Dystonie, Chorea</li>
<li><strong>3. Krampfanf√§lle:</strong> Oft therapieresistent, various Formen</li>
</ul>

<p><strong>Zus√§tzliche Symptome:</strong></p>
<ul>
<li><strong>Verhaltensst√∂rungen:</strong> Autismus-√§hnliche Z√ºge, Reizbarkeit</li>
<li><strong>Schlafst√∂rungen:</strong> Insomnie, ver√§nderte Schlafarchitektur</li>
<li><strong>Dysautonomie:</strong> Temperaturregulation, Hypersalivation</li>
</ul>
</div>

<table class="clinical-table">
<thead>
<tr>
<th>Ursache CFD</th>
<th>Mechanismus</th>
<th>H√§ufigkeit</th>
<th>Therapeutisches Ansprechen</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FOLR1-Autoantik√∂rper</strong></td>
<td>Blockade des Folat-Rezeptors</td>
<td>75% der F√§lle</td>
<td>Gut (hohe Folins√§ure-Dosen)</td>
</tr>
<tr>
<td><strong>FOLR1-Mutationen</strong></td>
<td>Struktureller Rezeptordefekt</td>
<td>15% der F√§lle</td>
<td>Variabel</td>
</tr>
<tr>
<td><strong>PCFT-Mutationen</strong></td>
<td>Gest√∂rter choroidaler Transport</td>
<td>5% der F√§lle</td>
<td>M√§√üig</td>
</tr>
<tr>
<td><strong>Mitochondriale Defekte</strong></td>
<td>Sekund√§re CSF-Folat-Reduktion</td>
<td>5% der F√§lle</td>
<td>Schlecht</td>
</tr>
</tbody>
</table>
</div>

<div class="subsection">
<h3>PCFT-Mangel (Heredit√§re Folat-Malabsorption)</h3>

<div class="case-study">
<h4>ü©∏ Klinisches Bild</h4>
<p><strong>Systemische Manifestationen:</strong></p>
<ul>
<li><strong>H√§matologisch:</strong> Megaloblastenan√§mie ab 1-6 Monaten</li>
<li><strong>Neurologisch:</strong> Krampfanf√§lle, Entwicklungsr√ºckstand</li>
<li><strong>Immunologisch:</strong> Rezidivierende Infekte, T-Zell-Defekt</li>
<li><strong>Gastrointestinal:</strong> Diarrh√∂, Malabsorption</li>
</ul>

<p><strong>Laborcharakteristika:</strong></p>
<ul>
<li><strong>Serum-Folat:</strong> Stark erniedrigt (<5 nmol/l)</li>
<li><strong>Homocystein:</strong> Erh√∂ht (>50 Œºmol/l)</li>
<li><strong>MCV:</strong> Deutlich erh√∂ht (>110 fl)</li>
<li><strong>CSF-Folat:</strong> Sekund√§r erniedrigt</li>
</ul>
</div>

<div class="pathway-diagram">
<h4>PCFT-Funktion und Defekt</h4>
<div style="display: flex; flex-direction: column; align-items: center; gap: 15px; margin: 20px 0;">
<div style="background: #f0fdf4; padding: 15px; border-radius: 8px; text-align: center; border: 1px solid #22c55e;">
<h5 style="color: #166534;">Normale PCFT-Funktion</h5>
<div style="display: flex; align-items: center; justify-content: center; gap: 10px; margin: 10px 0;">
<div class="enzyme-box">5-MTHF (pH 5,5)</div>
<span class="arrow">‚Üí</span>
<div class="enzyme-box">PCFT</div>
<span class="arrow">‚Üí</span>
<div class="enzyme-box">5-MTHF intrazellul√§r</div>
</div>
<p style="font-size: 0.9em; color: #166534;">Optimaler Transport bei pH 5,5 (Duodenum)</p>
</div>

<div style="background: #fef2f2; padding: 15px; border-radius: 8px; text-align: center; border: 1px solid #ef4444;">
<h5 style="color: #dc2626;">PCFT-Mangel</h5>
<div style="display: flex; align-items: center; justify-content: center; gap: 10px; margin: 10px 0;">
<div class="enzyme-box">5-MTHF</div>
<span class="arrow">‚Üí</span>
<div class="enzyme-box defect">PCFT ‚Üì</div>
<span class="arrow">‚Üí</span>
<div class="metabolite-box" style="background: linear-gradient(135deg, #dc2626, #b91c1c);">Malabsorption</div>
</div>
<p style="font-size: 0.9em; color: #dc2626;">Schwere systemische Folat-Defizienz</p>
</div>
</div>
</div>
</div>

<div class="subsection">
<h3>Diagnostik der Folat-Defekte</h3>

<div class="diagnostic-flow">
<div class="flow-step">
<strong>Verdacht</strong><br>
Neurologische Symptome +<br>
normale/niedrige Folat-Werte
</div>
<div class="flow-arrow"></div>
<div class="flow-step">
<strong>CSF-Folat</strong><br>
Lumbalpunktion<br>
5-MTHF Bestimmung
</div>
<div class="flow-arrow"></div>
<div class="flow-step">
<strong>FOLR1-Antik√∂rper</strong><br>
Serum und CSF<br>
Blockierende Antik√∂rper
</div>
<div class="flow-arrow"></div>
<div class="flow-step">
<strong>Molekulargenetik</strong><br>
FOLR1, SLC46A1, DHFR<br>
Targeted Sequencing
</div>
</div>

<table class="clinical-table">
<thead>
<tr>
<th>Parameter</th>
<th>Normal</th>
<th>CFD</th>
<th>PCFT-Mangel</th>
<th>DHFR-Mangel</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Serum-Folat</strong></td>
<td>10-45 nmol/l</td>
<td>Normal</td>
<td><5 nmol/l</td>
<td>Variabel</td>
</tr>
<tr>
<td><strong>CSF-Folat</strong></td>
<td>>40 nmol/l</td>
<td><10 nmol/l</td>
<td><5 nmol/l</td>
<td>Niedrig</td>
</tr>
<tr>
<td><strong>FOLR1-Antik√∂rper</strong></td>
<td>Negativ</td>
<td>75% positiv</td>
<td>Negativ</td>
<td>Negativ</td>
</tr>
<tr>
<td><strong>Homocystein</strong></td>
<td><15 Œºmol/l</td>
<td>Normal</td>
<td>>50 Œºmol/l</td>
<td>Erh√∂ht</td>
</tr>
<tr>
<td><strong>MCV</strong></td>
<td>70-90 fl</td>
<td>Normal</td>
<td>>110 fl</td>
<td>Erh√∂ht</td>
</tr>
</tbody>
</table>

<div class="highlight-box">
<h4>FOLR1-Autoantik√∂rper-Test</h4>
<p><strong>Indikationen:</strong></p>
<ul>
<li>CSF-Folat <10 nmol/l bei normalen Serum-Folat-Werten</li>
<li>Therapieresistente Epilepsie mit Entwicklungsr√ºckstand</li>
<li>Autismus-Spektrum-St√∂rung mit neurologischer Progression</li>
</ul>

<p><strong>Testverfahren:</strong></p>
<ul>
<li><strong>Bindungs-Assay:</strong> Kompetitive Hemmung der Folat-Bindung</li>
<li><strong>Cut-off:</strong> >5 pmol/l (serum), >0,5 pmol/l (CSF)</li>
<li><strong>Interpretation:</strong> Hohe Titer korrelieren mit klinischer Schwere</li>
</ul>
</div>
</div>

<div class="subsection">
<h3>Therapie der Folat-Defekte</h3>

<div class="case-study">
<h4>üíä Zerebrale Folat-Defizienz</h4>
<p><strong>Folins√§ure (5-Formyltetrahydrofolat):</strong></p>
<ul>
<li><strong>Dosierung:</strong> 0,5-1 mg/kg/d in 2-3 Dosen</li>
<li><strong>Maximum:</strong> Bis 40 mg/d bei schweren F√§llen</li>
<li><strong>Rationale:</strong> Umgeht FOLR1-Blockade</li>
<li><strong>Monitoring:</strong> CSF-Folat alle 6-12 Monate</li>
</ul>

<p><strong>Zusatztherapien:</strong></p>
<ul>
<li><strong>Immunsuppression:</strong> Bei nachgewiesenen Autoantik√∂rpern</li>
<li><strong>Steroide:</strong> Prednisolon 1-2 mg/kg/d √ºber 2-4 Wochen</li>
<li><strong>IVIG:</strong> 2 g/kg √ºber 2-5 Tage</li>
<li><strong>Rituximab:</strong> Bei therapieresistenten F√§llen</li>
</ul>
</div>

<table class="clinical-table">
<thead>
<tr>
<th>Defekt-Typ</th>
<th>Prim√§rtherapie</th>
<th>Dosierung</th>
<th>Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CFD (Autoantik√∂rper)</strong></td>
<td>Folins√§ure + Immunsuppression</td>
<td>1-3 mg/kg/d</td>
<td>CSF-Folat, Antik√∂rper-Titer</td>
</tr>
<tr>
<td><strong>CFD (FOLR1-Mutation)</strong></td>
<td>Hochdosis Folins√§ure</td>
<td>2-5 mg/kg/d</td>
<td>CSF-Folat, Klinik</td>
</tr>
<tr>
<td><strong>PCFT-Mangel</strong></td>
<td>Folins√§ure + Folat</td>
<td>15-20 mg/d</td>
<td>Blutbild, Homocystein</td>
</tr>
<tr>
<td><strong>DHFR-Mangel</strong></td>
<td>Folins√§ure</td>
<td>5-10 mg/d</td>
<td>Blutbild, Immunstatus</td>
</tr>
</tbody>
</table>

<div class="highlight-box">
<h4>Therapeutisches Ansprechen und Prognose</h4>
<p><strong>Beste Prognose (CFD mit Autoantik√∂rpern):</strong></p>
<ul>
<li><strong>Fr√ºhe Diagnose:</strong> Normale Entwicklung m√∂glich</li>
<li><strong>Kombinationstherapie:</strong> Folins√§ure + Immunsuppression</li>
<li><strong>Monitoring:</strong> Antik√∂rper-Titer als Verlaufsparameter</li>
</ul>

<p><strong>Variable Prognose (genetische Formen):</strong></p>
<ul>
<li><strong>PCFT-Mangel:</strong> Gut bei fr√ºher Diagnose und Therapie</li>
<li><strong>FOLR1-Mutationen:</strong> Abh√§ngig von Restfunktion</li>
<li><strong>Irreversible Sch√§den:</strong> Bei sp√§ter Diagnose m√∂glich</li>
</ul>

<p><strong>Verlaufsparameter:</strong></p>
<ul>
<li><strong>CSF-Folat:</strong> Ziel >20 nmol/l</li>
<li><strong>Klinisch:</strong> Krampfkontrolle, motorische Entwicklung</li>
<li><strong>MRT:</strong> Myelinisierung, Atrophie-Progression</li>
</ul>
</div>
</div>

<div class="next-step">
<button class="next-btn" onclick="showSection('quiz')">Zur Lernkontrolle ‚Üí</button>
</div>
</div>

<!-- Quiz/Lernkontrolle -->
<div class="content-section" id="quiz">
<h2 class="section-title">üéØ Lernkontrolle</h2>

<div class="quiz-container">
<div class="quiz-question">1. Welche Aussage zum Biotinidase-Mangel ist korrekt?</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">A) F√ºhrt zu prim√§rem Biotin-Mangel</div>
<div class="quiz-option" onclick="selectAnswer(this, true)">B) St√∂rt das Recycling von Biotin aus biotinylierten Proteinen</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">C) Manifestiert sich typischerweise neonatal</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">D) Spricht nicht auf Biotin-Therapie an</div>
</div>

<div class="quiz-container">
<div class="quiz-question">2. Was ist charakteristisch f√ºr die Multiple Carboxylase-Defizienz vom fr√ºhen Typ?</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">A) Manifestation erst nach dem 1. Lebensjahr</div>
<div class="quiz-option" onclick="selectAnswer(this, true)">B) Massive Erh√∂hung von 3-Methylcrotonyl-Glycin</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">C) Exzellentes Ansprechen auf Standard-Biotin-Dosen</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">D) Biotinidase-Aktivit√§t ist erniedrigt</div>
</div>

<div class="quiz-container">
<div class="quiz-question">3. Bei welchem Cobalamin-Defekt findet sich die Kombination aus erh√∂htem Methylmalonat UND erh√∂htem Homocystein?</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">A) cblA-Defekt</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">B) cblB-Defekt</div>
<div class="quiz-option" onclick="selectAnswer(this, true)">C) cblC-Defekt</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">D) cblE-Defekt</div>
</div>

<div class="quiz-container">
<div class="quiz-question">4. Was ist charakteristisch f√ºr die zerebrale Folat-Defizienz?</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">A) Erniedrigtes Serum-Folat</div>
<div class="quiz-option" onclick="selectAnswer(this, true)">B) Erniedrigtes CSF-Folat bei normalem Serum-Folat</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">C) Megaloblastenan√§mie</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">D) Erh√∂htes Methylmalonat</div>
</div>

<div class="quiz-container">
<div class="quiz-question">5. Welche irreversiblen Komplikationen k√∂nnen bei versp√§teter Biotinidase-Mangel-Therapie auftreten?</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">A) Nur dermatologische Ver√§nderungen</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">B) Nur neurologische Defizite</div>
<div class="quiz-option" onclick="selectAnswer(this, true)">C) H√∂rverlust und Optikusatrophie</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">D) Kardiomyopathie</div>
</div>

<div class="quiz-container">
<div class="quiz-question">6. Was ist das Therapieziel bei cblC-Defekt?</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">A) Normalisierung von Cobalamin im Serum</div>
<div class="quiz-option" onclick="selectAnswer(this, true)">B) Reduktion von Methylmalonat und Homocystein</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">C) Erh√∂hung der Methionin-Synthase-Aktivit√§t</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">D) Normalisierung des Folat-Status</div>
</div>

<div class="quiz-container">
<div class="quiz-question">7. Bei PCFT-Mangel (heredit√§re Folat-Malabsorption) findet sich typischerweise:</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">A) Normale h√§matologische Parameter</div>
<div class="quiz-option" onclick="selectAnswer(this, true)">B) Megaloblastenan√§mie und neurologische Symptome</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">C) Erh√∂htes Serum-Folat</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">D) Isolierte ZNS-Symptomatik</div>
</div>

<div class="quiz-container">
<div class="quiz-question">8. Welche Therapie ist bei zerebraler Folat-Defizienz mit FOLR1-Autoantik√∂rpern indiziert?</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">A) Nur hochdosierte Fols√§ure</div>
<div class="quiz-option" onclick="selectAnswer(this, true)">B) Folins√§ure plus Immunsuppression</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">C) Nur Immunsuppression</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">D) Cobalamin-Supplementation</div>
</div>

<div class="quiz-container">
<div class="quiz-question">9. Was unterscheidet die sp√§te von der fr√ºhen Form der Multiple Carboxylase-Defizienz?</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">A) Die betroffenen Carboxylasen</div>
<div class="quiz-option" onclick="selectAnswer(this, true)">B) Der zugrundeliegende Enzymdefekt</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">C) Das Muster der organischen S√§uren</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">D) Die Biotin-Responsivit√§t</div>
</div>

<div class="quiz-container">
<div class="quiz-question">10. Bei welchem Defekt kann trotz normaler Vitamin-Spiegel im Serum ein funktioneller Vitaminmangel vorliegen?</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">A) Nur bei Biotinidase-Mangel</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">B) Nur bei Cobalamin-Defekten</div>
<div class="quiz-option" onclick="selectAnswer(this, false)">C) Nur bei zerebraler Folat-Defizienz</div>
<div class="quiz-option" onclick="selectAnswer(this, true)">D) Bei allen genannten Defekten</div>
</div>

<div class="next-step">
<div style="text-align: center; margin-top: 2rem; padding: 2rem; background: linear-gradient(135deg, #eff6ff, #dbeafe); border-radius: var(--border-radius); border: 2px solid var(--info-color);">
<h3 style="color: var(--info-color); margin-bottom: 1rem;">üéâ Lerneinheit abgeschlossen!</h3>
<p style="color: var(--text-secondary); margin-bottom: 1.5rem;">Sie haben alle wichtigen Vitamin-/Cofaktor-Defekte systematisch durchgearbeitet.</p>
<div class="completion-badge">Experten-Level erreicht! üèÜ</div>
</div>
</div>
</div>

</div>

<script>
let currentSection = 0;
const sections = ['biotinidase', 'carboxylase', 'cobalamin', 'folsaeure', 'quiz'];
let quizScore = 0;
let questionsAnswered = 0;

function showSection(sectionId) {
// Hide all sections
const allSections = document.querySelectorAll('.content-section');
allSections.forEach(section => section.classList.remove('active'));

// Remove active class from all nav buttons
const allButtons = document.querySelectorAll('.nav-btn');
allButtons.forEach(btn => btn.classList.remove('active'));

// Show selected section
document.getElementById(sectionId).classList.add('active');

// Highlight active nav button
const activeButton = Array.from(allButtons).find(btn => 
btn.onclick.toString().includes(sectionId)
);
if (activeButton) {
activeButton.classList.add('active');
}

// Update progress bar
currentSection = sections.indexOf(sectionId);
const progress = ((currentSection + 1) / sections.length) * 100;
document.getElementById('progressBar').style.width = progress + '%';

// Scroll to top
window.scrollTo(0, 0);
}

function selectAnswer(element, isCorrect) {
// Prevent multiple selections
if (element.parentNode.classList.contains('answered')) {
return;
}

// Mark container as answered
element.parentNode.classList.add('answered');
questionsAnswered++;

// Style the selected answer
if (isCorrect) {
element.classList.add('correct');
quizScore++;
} else {
element.classList.add('incorrect');
// Also highlight the correct answer
const options = element.parentNode.querySelectorAll('.quiz-option');
options.forEach(option => {
if (option.onclick.toString().includes('true')) {
option.classList.add('correct');
}
});
}

// Show score if all questions answered
if (questionsAnswered === 10) {
setTimeout(() => {
const percentage = (quizScore / 10) * 100;
let message = '';
if (percentage >= 90) {
message = `Exzellent! ${quizScore}/10 Punkten (${percentage}%) - Sie beherrschen das Thema perfekt! üèÜ`;
} else if (percentage >= 70) {
message = `Gut! ${quizScore}/10 Punkten (${percentage}%) - Solide Kenntnisse mit kleinen L√ºcken. üëç`;
} else if (percentage >= 50) {
message = `Befriedigend! ${quizScore}/10 Punkten (${percentage}%) - Grundkenntnisse vorhanden, bitte wiederholen Sie die Inhalte. üìö`;
} else {
message = `${quizScore}/10 Punkten (${percentage}%) - Bitte arbeiten Sie die Lerneinheit nochmals durch. üí™`;
}
alert(message);
}, 1000);
}
}

// Initialize progress bar
document.getElementById('progressBar').style.width = '20%';
</script>
</body>
</html>
